Search a ticker

Categories
Biotech Stocks Featured Investing Stocks to Watch

Best Biotech Stocks To Watch In 2021? 4 To Know

With the health care industry coming into focus again, these biotech stocks could be worth considering.

best biotech stocks 2021

Do You Have These Top Biotech Stocks On Your Radar Today?

With the global pandemic raging on, biotech stocks have and continue to take center stage in the stock market today. This would be the case since Pfizer’s (NYSE: PFE) and BioNTech’s (NASDAQ: BNTX) initial coronavirus vaccine breakthrough late last year. Not only is the importance of the industry being discussed daily but the general public is learning more about the internal processes as well. As a result, new and seasoned investors alike could be seeing value among biotech stocks more than before now.

Overall, as the delta variant of the coronavirus continues to wreak havoc across the globe, these trends could persist. Sure, companies such as Moderna (NASDAQ: MRNA) are actively looking for new means of combating the virus. This would be where additional booster shots come into play. Aside from that, the biotech industry remains hard at work researching treatments for countless other deadly diseases. Just last week, BeyondSpring (NASDAQ: BYSI) revealed positive topline results from trials of its Non-Small Cell Lung Cancer treatment. Since then, BYSI stock has skyrocketed by over 140%. In the case that all this has you keen on the sector, here are four top biotech stocks to watch in the stock market now.

Best Biotech Stocks To Buy [Or Avoid] Now

CRISPR Therapeutics AG

CRISPR Therapeutics is a biotech company with headquarters in Zug, Switzerland. It is a leading gene-editing company that is focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. The platform will allow the company to make precise and directed changes to genomic DNA. With that, the company has established a portfolio of therapeutic programs across a broad range of disease areas. This includes oncology, regenerative medicine, and rare diseases. CRSP stock currently trades at $134.45 as of 2:16 p.m. ET and is up by over 45% in the past year.

In late July, the CRISPR provided a business update for its pipelines and reported its second-quarter financials. Among the highlights, the company received Orphan Drug Designation (ODD) for Phase 1 clinical trial of its CTX130 candidate for the treatment of T-cell lymphoma. CTX130 is an investigational therapy that targets a cluster of differentiation 70, or CD70, an antigen expressed on various solid tumors and hematologic malignancies.

The company also ended the quarter with $2.59 billion in cash, cash equivalents, and marketable securities. The company also reported total collaboration revenue was $900.2 million for the quarter, primarily consisting of the $900 million upfront payment from Vertex Pharmaceuticals. All things considered, will you watch CRSP stock?

Source: TD Ameritrade TOS

[Read More] 4 Artificial Intelligence Stocks To Watch Right Now

Cassava Sciences Inc.

Cassava Sciences is a clinical-stage biopharma company that discovers and develops innovations for chronic, neurodegenerative conditions. In essence, the company combines state-of-the-art technology with new insights in neurobiology to develop novel solutions for Alzheimer’s disease. SAVA stock currently trades at $123.99 as of 2:19 p.m. ET and is up by a whopping 1,645% year-to-date. On August 3, 2021, the company reported its second-quarter financials.

Firstly, Cassava reported that it ended the quarter with $278.3 million in cash and has no debt. Net cash used for operations for the full year 2021 is expected to be approximately $20 to $25 million. This is driven by higher headcount and personnel expenses and manufacturing costs around large-scale drug supply.

On July 29, 2021, the company also announced that its Simufilam drug significantly improves cognition in patients with Alzheimer’s in an interim analysis of an open-label study at 9 months. “We are very pleased with the overall consistency of data,” said Remi Barbier, President & CEO. “Simufilam improved cognition, biomarkers, and behavior, a triple-win for study participants. These clinical data combined with a clean safety profile and easy oral administration suggest highly encouraging and durable treatment effects for people living with Alzheimer’s disease.” With that being said, will you consider adding SAVA stock to your watchlist?

Source: TD Ameritrade TOS

[Read More] Best Stocks To Invest In 2021? 4 E-Commerce Stocks To Know

AbbVie Inc.

AbbVie is a biopharmaceutical company that is based in Illinois. The company develops innovative medicines to solve serious health issues today. Its key therapeutic areas include immunology, oncology, neuroscience, and virology for instance. Furthermore, it boasts a large pipeline of drugs and therapies. Notably, this includes treatments for ulcerative colitis and rheumatoid arthritis. ABBV stock currently trades at $115.66 as of 2:26 p.m. ET.

On July 30, 2021, the company announced a strong second quarter. It delivered net revenue of $13.96 billion, an increase of 33.9% year-over-year. A chunk of this revenue came from its immunology portfolio, at $6.12 billion, an increase of 15.1% compared to a year earlier. The company also reported diluted earnings per share of $0.42 for the quarter. With that in mind, do you think ABBV stock is a top biotech stock to watch right now?

Source: TD Ameritrade TOS

[Read More] 4 Semiconductor Stocks To Watch Right Now

C4 Therapeutics Inc.

Last but not least, we will be taking a look at C4 Therapeutics. In brief, the company specializes in researching small-molecule drugs that “selectively destroy disease-causing proteins via degradation”. C4 achieves this via the innate mechanisms within human cells. According to the company, this means of treatment provides several key advantages over conventional treatments today. This includes the potential to treat a wider array of diseases, higher potency, and less undesired side effects. As it stands, CCCC stock currently trades at $39.13 as of 2:27 p.m. ET after gaining by over 8%.

Notably, CCCC stock appears to be benefitting from the company’s latest announcement. Yesterday, C4 revealed that the FDA has granted ODD to its multiple myeloma treatment. In detail, an ODD from the FDA would benefit C4’s treatment in several ways. This mainly includes financial incentives and up to seven years of market exclusivity after receiving U.S. regulatory approval.

Also, this would be a win for C4 on the operational front. According to chief medical officer Adam Crystal, the company remains on course to advance its Phase 1/2 trials. After considering all of this, will you be adding CCCC stock to your portfolio?

Source: TD Ameritrade TOS

By Jonathan Phillip

Jonathan Phillip is an up and coming financial contributor in the stock market today. He's found a strong niche in writing about true growth industries. His main focus for the last 5 years has been on the cannabis industry and marijuana stocks. He is one of the top contributors to cannabis media outlets like MarijuanaStocks.com. He also is head of social media management for StockMarket.com.

Since an early age, Jonathan has been an active member of the cannabis culture. Coming from Miami, Florida, he's been able to identify emerging trends in the space including the emergence of cannabis derivatives, vapes, e-liquids, wax, and more. His ability to identify emerging niches has afforded him the ability to source valuable information from top industry names.

Jonathan has also managed to build a strong social media presence for companies. He has worked with hundreds of public companies to develop a digital presence. As an active blogger and social media influencer, his focus is on lifestyle segments of the market. You can find Jonathan reporting on anything from industry conferences and investor events to corporate disclosures and cannabis market movers.

Since the early days of marijuana companies going public, Jonathan has made it a point to find information before the crowd. The main target of his writing is on undiscovered or under-researched companies that could hold true, lasting market potential. Through his research, Jonathan has managed to be one of the early writers to identify the opportunity of cannabis over other things like alcohol and he was one of the first reporters to cover the multi-billion dollar deals that materialized in 2017 and 2018. He has also covered the emergence of multi-state operators in the U.S. after Canada paved the way in late 2018 and 2019 for legalization in North America.

Jonathan is also an active member of the underground hip-hop scene. He has worked with some of the biggest names in the rap community while also gaining valuable insight from top producers and business moguls focused on moving brands forward. In his free time, Jonathan builds social communities and continues to hone his skills as a leading financial writer.

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments